Tarsus Pharmaceuticals, Inc.
TARS
Peringkat dalam Saham
#4560
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Harga Saham
$71.65
Kapitalisasi Pasar
$3.35B
Perubahan (1 hari)
0.88%
Perubahan (1 tahun)
1.17%
Negara
US
Perdagangan Tarsus Pharmaceuticals, Inc. (TARS)
Kategori
Healthcare
Pendapatan untuk Tarsus Pharmaceuticals, Inc. (TARS)
Pendapatan pada Jun 2026 TTM: $606.33M
Menurut laporan keuangan terbaru dari Tarsus Pharmaceuticals, Inc., pendapatan saat ini (TTM) adalah $606.33M. Pada tahun 2023, perusahaan menghasilkan pendapatan sebesar $17.45M penurunan dibandingkan dengan pendapatan pada tahun 2022 yang sebesar $25.82M. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Tarsus Pharmaceuticals, Inc. dari 2018 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Mengubah |
|---|---|---|
| 2026 (TTM) | $606.33M | 231.41% |
| 2024 | $182.95M | 948.62% |
| 2023 | $17.45M | -32.42% |
| 2022 | $25.82M | -54.73% |
| 2021 | $57.03M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Pendapatan untuk perusahaan serupa atau pesaing
| Perusahaan | Pendapatan | Perbedaan Pendapatan | Negara |
|---|---|---|---|
| $12.62B | 1,982.08% |
US
|
|
| $2.23B | 267.46% |
US
|
|
| $15.74B | 2,496.66% |
AU
|
|
| $6.02B | 893.07% |
NL
|
|
| - | - |
CH
|
